Former FDA Commissioner: COVID-19 vaccine may be seasonal

Former FDA Commissioner Scott Gottlieb expects a vaccine for the new coronavirus, COVID-19, will be seasonal, akin to a flu shot.

“This is probably going to be a seasonal vaccine, the coronavirus vaccine,” Gottlieb said. “probably a vaccine we’re going to need to take every year.”

Gottlieb made the remarks during an interview with CNBC’s Squawk Box. Gottlieb also said the vaccine likely won’t be similar to polio or measles vaccines, where one dose can protect a person for life.

“You’re going to need to take this shot regularly, or maybe annually,” he said, adding that the agency does not yet know how long immunity from the vaccine will last.

The comments come after White House health advisor and director of the National Institute of Allergy and Infectious Disease (NIAID) Anthony Fauci, MD, said immunity from the vaccine is likely to last less than a year. At the same time, Fauci was hopeful the U.S. would have hundreds of millions of doses of an effective vaccine by early 2021.

Gottlieb served as chief of the FDA from May 11, 2017, to April 5, 2019.

See the full interview below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.